Fig. 1From: Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapyTimeline: a-b CT scans of the abdomen with splenic metastases and a iliac lymph node metastasis before the first dose of pembrolizumab. c-d CT scans of the abdomen with splenic metastases and a iliac lymph node metastasis after one dose of pembrolizumab and acute kidney injury. e-f CT scans of the abdomen with a fulminant response of the splenic metastases and the iliac lymph node metastasis after three doses of ipilimumab/nivolumab. White arrows indicate metastasesBack to article page